Clinical Trial Update: NEO6860, a TRPV1 Antagonist, First in Human Study [Phase 1]

View source ↗

Summary

NEO6860, a TRPV1 antagonist, has completed its first-in-human Phase 1 study. The trial focused on knee osteoarthritis and was sponsored by Neomed Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• NEO6860

Snippet

Sponsor: Neomed Institute | Conditions: Osteoarthritis, Knee | Phase 1 | Status: COMPLETED